CliniMACS® CD34 Product Line

CD34 Product Line

The CD34 antigen is a single transmembrane glycoprotein that is mainly expressed on human hematopoietic stem and progenitor cells but is also present on endothelial progenitor cells.
The CD34 antigen is involved in cell adhesion and is thought to function as a signaling molecule.
The CliniMACS® CD34 Product Line consists of murine anti-CD34 monoclonal antibodies conjugated to superparamagnetic iron dextran particles.
One vial contains 7.5 mL sterile, non-pyrogenic solution.
The performance of the CliniMACS CD34 Product Line depends on the individual separation strategy. For information on respective capacities, refer to the CliniMACS User Manual or contact your local representative.
Please inquire about required CliniMACS System components and accessories.


The CliniMACS
System components, including Reagents, Tubing Sets, Instruments, and PBS/EDTA Buffer, are designed, manufactured and tested under a quality system certified to ISO 13485.
In the EU, the CliniMACS System components are available as CE-marked medical devices for their respective intended use, unless otherwise stated. The CliniMACS Reagents and Biotin Conjugates are intended for in vitro use only and are not designated for therapeutic use or direct infusion into patients. The CliniMACS Reagents in combination with the CliniMACS System are intended to separate human cells. Miltenyi Biotec as the manufacturer of the CliniMACS System does not give any recommendations regarding the use of separated cells for therapeutic purposes and does not make any claims regarding a clinical benefit. For the manufacturing and use of target cells in humans the national legislation and regulations - e.g., for the EU the Directive 2004/23/EC ("human tissues and cells"), or the Directive 2002/98/EC ("human blood and blood components") - must be followed. Thus, any clinical application of the target cells is exclusively within the responsibility of the user of a CliniMACS System.
In the US, the CliniMACS CD34 Reagent System, including the CliniMACS Plus Instrument, CliniMACS CD34 Reagent, CliniMACS Tubing Sets TS and LS, and the CliniMACS PBS/EDTA Buffer, is FDA approved; all other products of the CliniMACS Product Line are available for use only under an approved Investigational New Drug (IND) application or Investigational Device Exemption (IDE).
CliniMACS MicroBeads are for research use only and not for human therapeutic or diagnostic use. Unless otherwise specifically indicated, Miltenyi Biotec products and services are for research only and not for therapeutic or diagnostic use.


The CliniMACS CD34 Product Line was developed for the enrichment of CD34
cells from human heterogeneous hematologic cell populations in combination with the CliniMACS System.

Referenced literature

CD34 enrichment of hematopoietic progenitor cells (HPC) is performed to provide an allogeneic stem cell graft highly purified for CD34
cells and depleted of unwanted cells.
Highly purified CD34
enriched stem cell grafts were reportedly used for HLA mismatched (MMUD/MMRD) and haploidentical hematopoietic stem cell transplantations (haplo-HSCT)
, as well as for HLA identical sibling (MRD) and matched unrelated donor (MUD) cell transplantations
. To overcome poor graft function (PGF) after HSCT CD34
selected stem cell boosts (SCB) were utilized in pediatrics and adults
. T cell depletion (TCD) facilitated by CD34
cell enrichment is also described in combination with reduced intensity conditioning (RIC)
and umbilical cord blood transplantation
. In addition outcomes of TCD in both malignant
and non-malignant diseases have been published
. Different methods of graft manipulation and future prospects of
ex vivo
TCD in allogeneic HSCT have been reviewed
In autologous transplantation CD34
progenitor cells can be enriched in order to passively remove tumor cells from the graft (tumor cell purging)
. Enriched CD34
cells have also been used to deplete auto-reactive cells from stem cell grafts for refractory autoimmune diseases, such as multiple sclerosis, severe scleroderma, systemic lupus erythematosus, and systemic sclerosis
. Genetically engineered hematopoietic stem cells for clinical gene therapy have been studied for over a decade and early limitations have been addressed
. The first
ex vivo
stem cell gene therapy for patients with ADA-SCID are commercially available autologous CD34
enriched cells transduced to express adenosine deaminase
Product options: -

Product information

Order no.

Related products

10 products available | view all